In this article, we will list the 5 Best Stocks Under $10 That Could Triple. Please visit 10 Best Stocks Under $10 That Could Triple if you’d like to see an extended list and the methodology behind it.

5. Omeros Corp. (NASDAQ:OMER)

Omeros Corp. (NASDAQ:OMER) is one of the 10 best stocks under $10 that could triple.

On June 26, Omeros Corp. (NASDAQ:OMER) released an update regarding the Committee for Medicinal Products for Human Use’s (CHMP) review of a marketing authorization application for the company’s narsoplimab.  This antibody targets MASP-2 to cure hematopoietic stem cell transplant-related thrombotic microangiopathy.

After an oral explanation meeting, Omeros stated that the CHMP adopted a negative opinion on the filing. The company plans to request a reconsideration of the opinion and seek assessment by an Ad Hoc Expert Panel, which is an independent group of external clinical and scientific specialists to be assembled by the EMA.

Later, on June 26, Brandon Folkes from H.C. Wainwright cut the price target on Omeros Corp. (NASDAQ:OMER) from $40 to $33, which still implies an adjusted upside of more than 233%. The analyst kept a Buy rating on the stock despite an unfavorable opinion on Yartemlea shared by the CHMP.

Folkes labeled this development as a short-term headwind but does not consider this to be a major hurdle for the stock’s long-term potential. Further, he pointed to the antibody’s U.S. launch as the key value driver. He highlighted that the reduced price target incorporates increased forward-looking outlays on R&D and the removal of the EU opportunity from its valuation model.

Omeros Corp. (NASDAQ:OMER) is a clinical-stage biopharmaceutical developer that specializes in the discovery and development of drugs for immunologic diseases and rare diseases. The company’s drug candidate, Narsoplimab, is intended for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy.

4. Lexeo Therapeutics Inc. (NASDAQ:LXEO)

Lexeo Therapeutics Inc. (NASDAQ:LXEO) is one of the 10 best stocks under $10 that could triple.

On June 15, Lexeo Therapeutics Inc. (NASDAQ:LXEO) disclosed that it has finalized the critical trial protocol of SUNRISE-FA 2. The company also finalized the statistical analysis plan meant to offer clinical evidence for submission of a Biologics License Application to the U.S. FDA.

The company highlighted that this submission is for the gene-based therapy candidate, LX2006, under the 2028 approval pathway. Lexeo’s Chief Medical Officer, Narinder Bhalla, M.D., labeled it as a major stride that involves the completion of a critical study design for SUNRISE-FA 2. He believes that it sets a path to assess LX2006 in Friedreich’s ataxia cardiomyopathy. He further stated:

“Patients living with FA, particularly those with cardiac involvement, have a significant unmet need for new treatment options and remain at the center of our efforts. This progress brings us one step closer to delivering a potential new therapy, and we remain focused on execution as we work to initiate the pivotal study and enroll the first patient by the end of the month.”

Later on June 25, JPMorgan reduced its target price for the stock from $12 to $9, which still yields an adjusted upside potential of over 92%. The firm reiterated an Overweight rating on the stock, based on a revised model that incorporates the company’s latest updates.

Lexeo Therapeutics Inc. (NASDAQ:LXEO) is a clinical-stage company that develops genetic medicines to treat genetic disorders. It is developing medicines which include an AAVrh10-based therapy known as LX2006, used for treating Friedreich’s ataxia associated with cardiomyopathy, and LX2020, which is developed to cure the heart muscles through gene delivery.

3. Sharplink Inc. (NASDAQ:SBET)

Sharplink Inc. (NASDAQ:SBET) is one of the 10 best stocks under $10 that could triple.

On June 30, Sharplink Inc. (NASDAQ:SBET) disclosed that it had purchased 10,000 Ether at an average price of $1,611 per ETH. This lifts its cumulative holdings to 886,725 tokens. The company also executed an open market buyback of more than 2.13 million of its common shares at an average rate of $4.69 per share, under its current stock repurchase program.

The company’s Chief Executive Officer, Joseph Chalom, reflected on Sharplink’s recently concluded $75 million registered direct offering, which he believes has improved the company’s financial standing and facilitated its dynamic strategy for ETH treasury management. He further stated:

“Our capital allocation philosophy is disciplined and straightforward: every financing decision we make is based on our long-term objective to increase ETH per share.”

Earlier on June 22, SharpLink Inc. (NASDAQ:SBET) revealed that it had signed an SPA with an institutional investor for the sale and purchase of more than 10 million of its common shares. The agreement also included attached warrants to buy common stock up to the designated amount. The underlying combined price was $7.49 per share and warrant, representing a 41% premium over the prevailing market price.

Sharplink Inc. (NASDAQ:SBET) focuses on the digital asset treasury business and operates as an institutional-grade Ethereum treasury platform. The company offers performance-based customer acquisition services for sportsbook and online casino gaming operators. It also drives user traffic and player acquisition for licensed gaming operators through PAS.net and a portfolio of U.S. state-specific digital properties.

2. ARS Pharmaceuticals Inc. (NASDAQ:SPRY)

ARS Pharmaceuticals Inc. (NASDAQ:SPRY) is one of the 10 best stocks under $10 that could triple.

On July 8, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) disclosed a CEO transition, and effective July 6, the company’s Co-founder and Chief Executive Officer, Richard Lowenthal, will no longer be employed by the company. Donn Casale, the company’s current President, has been appointed as the new CEO and Director, who will take charge from July 7 onwards.

The company shared that Casale has over 25 years of experience, covering the biopharma segment and commercial leadership roles. He has prior experience working as the Chief Commercial Officer with Dynavax Technologies, where he played a pivotal role in scaling up the annual revenues for hepatitis B cure, HEPLISAV-B(R), to more than $300 million. He helped the vaccine achieve more than 50% market share across the U.S. market prior to the acquisition of the company by Sanofi for $2.2 billion.

Back on June 24, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) shared an update on the payer access for neffy, which is an epinephrine nasal spray. Based on the latest feedback, no new coverage decisions or commercial formulary inclusions have been released for neffy during the July 1 cycle.

ARS Pharma plans to continue collaborating with the rest of the payers and stated that neffy remains widely available to commercially insured individuals via direct coverage and a recently added retail cash option.

ARS Pharmaceuticals Inc. (NASDAQ:SPRY) is a biopharmaceutical company that is creating and selling medications meant for serious allergic reactions. The company has developed a product, neffy, which allows for the administration of epinephrine attacks without using needles to treat allergic reactions such as anaphylaxis.

1. Sagimet Biosciences Inc. (NASDAQ:SGMT)

Sagimet Biosciences Inc. (NASDAQ:SGMT) is one of the 10 best stocks under $10 that could triple.

On June 29, Sagimet Biosciences Inc. (NASDAQ:SGMT) announced that it had been included in the broader Russell 3000 Index and the small-cap focused Russell 2000 Index, as part of the Russell Indexes reconstitution for 2026. The June index reconstitution incorporates about 4,000 of the largest U.S. companies, based on their market capitalization as of the April 30 close.

Inclusion in the Russell 3000 Index results in automatic addition to either the Russell 1000 Index or the Russell 2000 Index. It also leads to inclusions across indexes that cover value or growth tilts.

CEO David Happel said this development speaks volumes about what Sagimet has achieved over the years, with people now expecting the company to start its Phase 3 clinical study on denifanstat. He further stated:

“If approved, denifanstat would be the first innovative oral treatment for acne vulgaris in patients aged 12 years and older in more than forty years. With the capital in place to fund our programs through 2028, including data readout of our planned denifanstat Phase 3 clinical trial in acne, we look forward to the broader visibility that inclusion in the Russell indexes brings.”

Sagimet Biosciences Inc. (NASDAQ:SGMT) is a biopharmaceutical firm at the clinical stage making drug innovations based on fatty acid synthase. The company’s leading drug candidate is Denifanstat, which is an oral pill taken once a day to counter diseases associated with the malfunctioning of metabolic processes.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.